<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">The precise drivers of death, regardless of sex, in COVID-19 remain unknown. There appears to be a subset of patients in whom high levels of dysregulated inflammation lead to severe multisystem organ pathology
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>,
  <xref ref-type="bibr" rid="CR2">2</xref>
 </sup>. A postviral inflammatory syndrome has also emerged in children with COVID-19 (refs
 <sup>
  <xref ref-type="bibr" rid="CR3">3</xref>,
  <xref ref-type="bibr" rid="CR4">4</xref>
 </sup>). As a result, research on therapeutics has focused on both antiviral and immunomodulatory pathways
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>,
  <xref ref-type="bibr" rid="CR5">5</xref>
 </sup> with the goal of achieving an optimized balance in immune response induction and resolution. Unfortunately, most studies fail to consider the sex of the patients, which may mask therapeutic targets.
</p>
